7 completed, 2 terminated, 2 unknown, 2 withdrawn. 5 Phase 2, 5 Phase 4, 3 Phase 1, 2 Phase 3, 1 Not applicable.
Follow Canrenoic Acid: new trials by email Literature Review of Canrenoic Acid trials Research Report on Canrenoic Acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients Spironolactone Oral Suspension - Edema Due to Heart Failure or Cirrhosis | Phase 4 | Not yet recruiting | CMP Development, LLC | 96 | 2027-06-01 | 2026-10-22 |
| Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19 Potassium Canrenoate - COVID-19 Acute Respiratory Distress Syndrome | Phase 2 | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 180 | 2022-09-01 | 2022-05-20 |
| Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment UNa measurement after intravenous loop diuretic bolus, Intravenous acetazolamide 500 mg OD, Intravenous bumetanide TID - Acute Heart Failure, Diuretics Drug Reactions | Phase 4 | Completed | Vrije Universiteit Brussel | 107 | 2022-06-12 | 2026-09-11 |
| Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg - Transgender Health, Gender Dysphoria | Phase 1 | Completed | Thomas Jefferson University | 8 | 2022-01-04 | 2025-03-26 |
| Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial IV Potassium Canrenoate, IV Sodium Chloride 0.9 % - Brain-dead Organ Donors | Phase 2 | Active not recruiting | Pr. Nicolas GIRERD | 36 | 2021-08-26 | 2025-07-03 |
| Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment Torasemide, Spironolactone - Hypertension, Genetic Predisposition | Phase 3 | Completed | Ospedale San Raffaele | 38 | 2021-02-15 | 2024-05-16 |
| Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19. Canrenoate Potassium, Normal Saline - COVID-19 Pneumonia | Phase 4 | Unknown | Pomeranian Medical University Szczecin | 50 | 2021-01-01 | 2021-06-08 |
| Spironolactone for Hidradenitis Suppurativa Spironolactone 50 MG, Spironolactone 100mg, Spironolactone 200 mg - Hidradenitis Suppurativa | Phase 4 | Withdrawn | Medical University of South Carolina | 2020-09-21 | 2024-09-19 | |
| Spironolactone in Covid-19 Induced ARDS Spironolactone 100mg, Placebo oral tablet - Respiratory Distress Syndrome, Adult | Completed | Istanbul University - Cerrahpasa | 60 | 2020-05-05 | 2021-10-28 | |
| Spironolactone for the Treatment of Melasma Spironolactone 50Mg Tablet, Spironolactone 100Mg Tablet, Spironolactone 200Mg - Melasma | Phase 1 | Withdrawn | Medical University of South Carolina | 2020-03-05 | 2024-09-04 | |
| Spironolactone Therapy In Young Women With NASH Spironolactone 100mg, Placebo oral capsule - NASH - Nonalcoholic Steatohepatitis | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 20 | 2019-01-09 | 2025-03-26 |
| Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC) Spironolactone (+/- Furosemide) - Cancer | Phase 2 | Terminated | Centre Oscar Lambret | 14 | 2016-05-30 | 2019-05-16 |
| Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance Spironolactone 100mg, Spironolactone 25mg - Heart Failure | Phase 2 / Phase 3 | Completed | Columbia University | 20 | 2015-11-01 | 2019-08-08 |
| Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B Spironolactone 100mg, Spironolactone 200mg, Placebo - Patients With Fungic Infections | Phase 4 | Terminated | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 36 | 2013-05-01 | 2015-07-07 |
| Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System Spironolactone (Spironol) 25 mg - Chronic Kidney Disease, Proteinuria | Not applicable | Completed | Medical University of Gdansk | 2005-03-01 | 2007-09-12 |
COVID-19 (2) · Fibrosis (2) · Acquired Immunodeficiency Syndrome (1) · Edema (1) · Gender Dysphoria (1) · Genetic Predisposition to Disease (1) · Heart Failure (1) · Hidradenitis Suppurativa (1) · Hypertension (1) · Melanosis (1) · Neoplasms (1) · Non-alcoholic Fatty Liver Disease (1) · Pneumonia (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1)
Medical University of South Carolina (2) · CMP Development, LLC (1) · Centre Oscar Lambret (1) · Columbia University (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · Istanbul University - Cerrahpasa (1) · Medical University of Gdansk (1) · Ospedale San Raffaele (1) · Pomeranian Medical University Szczecin (1) · Pr. Nicolas GIRERD (1) · Thomas Jefferson University (1) · University of California, San Francisco (1) · Vrije Universiteit Brussel (1)
United States (4) · France (2) · Belgium (1) · Italy (1) · Mexico (1) · Poland (1) · Turkey (Türkiye) (1)
Dirk Elston, MD (2) · Arthur R Garan, MD (1) · Boleslaw Rutkowski, MD, PhD (1) · Frederik H Verbrugge, M.D.; Ph.D.; M.Sc. (1) · Gerald Sakowski (1) · Katarzyna L Kotfis, MD, PhD (1) · Marco Vicenzi, MD (1) · Monika A Sarkar (1) · Paolo Manunta, MD (1)
PMID 33107592, PMID 37466151, PMID 37821131, PMID 38421210, PMID 38447632